Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation

PURPOSE: Brentuximab vedotin, an effective anti-CD30 antibody-drug conjugate approved for use in adults with classical Hodgkin lymphoma (HL), was introduced in this frontline trial to reduce prescribed radiation in children and adolescents with classical HL. METHODS: Open-label, single-arm, multicen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Metzger, Monika L., Link, Michael P., Billett, Amy L., Flerlage, Jamie, Lucas, John T., Mandrell, Belinda N., Ehrhardt, Matthew J., Bhakta, Nickhill, Yock, Torunn I., Friedmann, Alison M., de Alarcon, Pedro, Luna-Fineman, Sandra, Larsen, Eric, Kaste, Sue C., Shulkin, Barry, Lu, Zhaohua, Li, Chen, Hiniker, Susan M., Donaldson, Sarah S., Hudson, Melissa M., Krasin, Matthew J.
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2021
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8260923/
https://ncbi.nlm.nih.gov/pubmed/33826362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.03286
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados